FDA's Oncologic Drugs Advisory Committee will re-examine valrubicin (AD32) for patients with biopsy-confirmed carcinoma in situ of the bladder refractory to Bacillus Calmette-Guerin vaccine on the afternoon of Sept. 1. The committee recommended against approval of Valstar (NDA 20-893) June 1 because the "complete response" endpoint was viewed as an insufficient measure of efficacy ("The Pink Sheet" June 8, p. 26). The company has submitted a reanalysis
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth